|Articles|June 15, 2002

BioPharm International-06-01-2002
Volume 15
Issue 6

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

On 19 April, a group of experts gathered to discuss key issues in the ongoing debate about stem cell research and related issues pertinent to xenotransplantation. Participants were Bill Anthony (moderator) of Orrick, Herrington and Sutcliffe; David J. Earp of Geron Corporation; Liz Howard of Orrick, Herrington and Sutcliffe; Wayne Koberstein of Pharmaceutical Executive; Thomas G. Sanders of MitoKor; and Margaret R. McLean of the Markkula Center for Applied Ethics, Santa Clara University.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 24 years ago

Article

Negotiating and Structuring Strategic Alliances

over 24 years ago

Article

Finding Funding in Biotechnology: Keeping the Companies Alive

over 24 years ago

Article

Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of Your Patent Portfolio

over 24 years ago

Article

Guest Editorial: Enabling Collaboration in the Pharmaceutical Industry

over 24 years ago

Article

Unlocking the Value of R&D: Managing the Risks

over 24 years ago

Article

Viewpoint: United Kingdom highlights biomanufacturing capabilities

over 24 years ago

Article

Creating Effective Biopharmaceutical QA/QC Organizations: Your People are the Key

over 24 years ago

Article

Inside Washington: Safety, Risk, and Biotechnology Regulation

over 24 years ago

Article

Criminal Penalties for Theft of Biological Material

over 24 years ago

Article

Outsourcing Outlook: E-Procurement - Reverse Auctions and the Seller's Perspective.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 22nd, 2026

Turn Supply Chain Data Into Decisions Before Shortages Reach Patients, Says RELEX’s Rohit Tripathi

Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.

Technologist in white protective uniform controlling industrial process using tablet computer. | Image credit: © littlewolf1989 - © littlewolf1989 - stock.adobe.com

October 22nd, 2026

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.

Structure of human eye. In side view. | Image credit: © svetazi - © svetazi - stock.adobe.com

October 22nd, 2026

Alcon Pays $550 Million for Neurotech and Its MacTel Cell Therapy

Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.

3D cross-section illustration of breast tissue showing pink lobes, milk ducts converging toward the nipple, and a dark red clustered mass representing a tumor. | Image Credit: © Design cells - stock.adobe.com

October 22nd, 2026

BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial

BioNTech and Bristol Myers Squibb will replace chemotherapy with Gilead’s TROP2-directed ADC sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial of PD-L1×VEGF-A bispecific pumitamig in PD-L1-low or -negative TNBC.

A clinician in a white coat with a stethoscope points a pen at an anatomical model showing the kidneys, renal blood vessels, aorta, vena cava, and ureters. | Image Credit: © Yanisa - stock.adobe.com

October 22nd, 2026

FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy

Alexion’s ravulizumab won accelerated approval to reduce proteinuria in adults with IgA nephropathy after the Phase 3 I CAN trial showed a 43.4% placebo-adjusted reduction at Week 34.

October 21st, 2026

The BioPharm Brief: Insulin Supply Security, a Bispecific Head-to-Head, and Long-Acting HIV Antibodies

Sanofi breaks ground on an EU-backed insulin API plant in Frankfurt, Summit and ECOG-ACRIN launch a phase 2/3 trial of ivonescimab in first-line biliary tract cancer, and TaiMed’s anti-CD4 antibody TMB-365 lowers HIV viral load in phase 1.

October 21st, 2026

Reshoring Should Be Judged by Risk Removed, Not Factories Moved, Says RELEX’s Rohit Tripathi

Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.

October 21st, 2026

Insilica’s Dr Luechtefeld Discusses Moving Computational Toxicology Beyond Predictive Models

At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

Articles in this issue

Related to this article

Trending on BioPharm International

Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt

Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US

TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens

Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial

Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation